SHANGHAI :
Yiling's Shares Hit All-Time High on Approved Covid-19 TCM Drug
Tang Shihua
DATE:  Apr 14 2020
/ SOURCE:  Yicai
Yiling's Shares Hit All-Time High on Approved Covid-19 TCM Drug Yiling's Shares Hit All-Time High on Approved Covid-19 TCM Drug

(Yicai Global) April 14 -- Yiling Pharmaceutical's stock price jumped to a historic high today after the Chinese firm said that the national drug regulator has given the green light for it to add Covid-19-related symptoms to the indications of use regarding its traditional Chinese medicine product.

Yiling's shares [SHE:002603] climbed by the daily ceiling of 10 percent to CNY31.32 (USD4.40) today.

The National Medical Products Administration has agreed that Lianhua Qingwen capsules can treat light Covid-19 symptoms, including "fever, cough, and lack of strength," the Hebei province-based company said in a statement.

A clinical trial involving 284 patients shows that using the drug helped nearly 92 percent of the patients recover, Zhong Nanshan, a famous respiratory disease expert, said last month.

Editor: Emmi Laine

Follow Yicai Global on
Keywords:   Regulatory Approval,New Indications,Virus Outbreak,New Coronavirus Pneumonia,Epidemic Control,Yiling Pharmaceutical